To explore the pathogenesis and scientific connotation of non-alcoholic fatty liver based on the theory of turbid toxin of traditional Chinese medicine

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a metabolic liver disease characterized by the accumulation of excessive liver lipids without alcohol-induced damage. It has emerged as a significant global health issue. A recent research has indicated that dysregulation of lipid decomposition, uptake, production, oxidation, and secretion causes alterations in various types of lipids, leading to organelle dysfunction and metabolic signaling pathway impairment. Scholars propose that turbid toxin is crucial in the pathogenesis of NAFLD. This article elucidates the meaning of turbid toxin in conjunction with the current literature and analyzes the modern pathophysiological mechanism underlying the development of NAFLD, including turbid toxic substance production, related organelle involvement, biological processes, and pathways, ultimately leading to disease outcomes. The relationship between traditional Chinese medicine and the turbid toxin is also explored to establish a foundation for further mechanistic research on NAFLD.

Keywords

molecular mechanism / non-alcoholic fatty liver disease / science connotation / signal pathway / turbid toxin

References

[1] Ge J , Xu Y , Wang C . Internal Medicine. People's Health Press; 2018: 391- 392 (in Chinese).

[2] Riazi K , Azhari H , Charette JH , et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022; 7 (9): 851- 861.

[3] Kim D , Kim WR . Nonobese fatty liver disease. Clin Gastroenterol Hepatol. 2017; 15 (4): 474- 485.

[4] Fan JG , Kim SU , Wong VW . New trends on obesity and NAFLD in Asia. J Hepatol. 2017; 67 (4): 862- 873.

[5] Wu L , Ge H , Liang D , Wang H . Research progress on the pathogenesis of nonalcoholic fatty liver disease. Chin Foreign Med Res. 2021; 19 (13): 193- 196 (in Chinese).

[6] Zhang X , Hu Z , Xu K , Li Y . Research progress in the prevention and treatment of nonalcoholic fatty liver disease by Chinese medicine. Henan TCM. 2021; 41 (9): 1427- 1431 (in Chinese).

[7] Cheng YP , Zhang MH . Research progress in the treatment of nonalcoholic fatty liver from phlegm and stasis theory. J Liaoning Univ TCM. 2018; 20 (11): 157- 160 (in Chinese).

[8] Huang HN , Fu YQ , Huang JJ , Zhang WF . Advances in the treatment of nonalcoholic fatty liver with Chinese medicine. Liaoning J TCM. 2020; 47 (11): 201- 203.

[9] Zhu K , Guo Y , Zhao C , et al. Etiology exploration of non-alcoholic fatty liver disease from traditional Chinese medicine constitution perspective: a cross-sectional study. Front Public Health. 2021; 9: 635818.

[10] Cheng H . Exploring the theory of cancer toxicity pathogenesis. J TCM. 2014; 55 (20): 1711- 1715 (in Chinese).

[11] Zheng H , Hou W , Hua B . Academic connotation of the qi-transferring and detoxification method and its practice in tumor prevention and treatment. J TCM. 2022; 63 (21): 2023- 2028 (in Chinese).

[12] Zhang X . Experimental discussion on the concept of “turbid toxin” in warm diseases and its clinical significance. J TCM. 1981; 1 (8): 5- 8 (in Chinese).

[13] Suo M , Li H , Zhao H , Zhang X . TCM master Zhang Xuewen0s experience in treating diabetic foot from endogenous toxin evil facto. Acta Chin Med. 2020; 35 (4): 807- 810 (in Chinese).

[14] Sun C . The understanding of “poison” in Chinese medicine. TCM Res. 2011; 24 (9): 1- 3 (in Chinese).

[15] An N , Lv JK , Han L . Traditional ideas of Chinese medicine and risk management strategies for new traditional Chinese medicine safety. CJPT. 2021; 35 (2): 90- 95 (in Chinese).

[16] Xu WC , Zhao RY , Li DG , Du YR , Lang XM . Turbid toxic syndrome supplements TCM syndrome. Chin J TCM Pharm. 2019; 34 (10): 4580- 4582 (in Chinese).

[17] Yang Q , Liu YT , Du Y . Yang Qian's treatment of nonalcoholic fatty liver from turbid toxicity. Liaoning J TCM. 2016; 43 (9): 1845- 1846 (in Chinese).

[18] Li D . Discussion on the innovation and development of traditional Chinese medicine from the perspective of establishment and application of turbidity theory. J TCM. 2020; 61 (22): 1938- 1940 (in Chinese).

[19] Jiang XQ , Liang HQ , Liu YY , Zheng XT , Wu YN . A case example of Wu Yaonan's application of the theory of “turbid toxicity” in the treatment of nonalcoholic fatty liver disease. Med Inf. 2020; 33 (4): 158- 159 (in Chinese).

[20] Zhao WX , Zhang LH , Liu XY . Zhang Lei's experience in treating non-alcoholic fatty liver disease with rinsing turbidity method. J TCM. 2019; 60 (23): 1993- 1996 (in Chinese).

[21] Yu Q , Cao L , Huang H , Tang B . Treatment of fatty liver from the theory of “turbid toxicity”. Hebei J TCM. 2014; 36 (1): 51- 65 (in Chinese).

[22] Ji AD . Li Junxiang's experience in treating nonalcoholic fatty liver. Liaoning J TCM. 2009; 36 (12): 2052- 2054 (in Chinese).

[23] Meza-Torres C , Hernández-Camacho JD , Cortés-Rodríguez AB , et al. Resveratrol regulates the expression of genes involved in CoQ synthesis in liver in mice fed with high fat diet. Antioxidants. 2020; 9 (5): 431.

[24] Guo L , Tang QQ . Research progress on the pathogenesis and treatment of nonalcoholic fatty liver. Chin Bull Life Sci. 2018; 30 (11): 1165- 1172 (in Chinese).

[25] Jin Y , Hu YY , Yang FQ . Regulatory T cells and nonalcoholic lipid liver disease. Chin J Immunol. 2019; 35 (11): 1394- 1398 (in Chinese).

[26] Musso G , Cassader M , Paschetta E , Gambino R . Bioactive lipid species and metabolic pathways in progression and resolution of nonalcoholic steatohepatitis. Gastroenterology. 2018; 155 (2): 282- 302.e8.

[27] Geng Y , Faber KN , de Meijer VE , Blokzijl H , Moshage H . How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease? Hepatol Int. 2021; 15 (1): 21- 35.

[28] Boursier J , Mueller O , Barret M , et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016; 63 (3): 764- 775.

[29] Hirsova P , Ibrahim SH , Gores GJ , Malhi H . Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis. J Lipid Res. 2016; 57 (10): 1758- 1770.

[30] Wellen KE , Thompson CB . A two-way street: reciprocal regulation of metabolism and signaling. Nat Rev Mol Cell Biol. 2012; 13 (4): 270- 276.

[31] Friedman SL , Neuschwander-Tetri BA , Rinella M , Sanyal AJ . Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018; 24 (7): 908- 922.

[32] Stols-Goncalves D , Hovingh GK , Nieuwdorp M , Holleboom AG . NAFLD and atherosclerosis: two sides of the same dysmetabolic coin? Trends Endocrinol Metabol. 2019; 30 (12): 891- 902.

[33] Zhang L , Wang YJ , Wu F , Wang X , Feng Y . MDG, an Ophiopogon japonicus polysaccharide, inhibits non-alcoholic fatty liver disease by regulating the abundance of Akkermansia muciniphila. Int J Biol Macromol. 2022; 196: 23- 34.

[34] Ke SJ , Yang HY , Liu LX . Research progress in the pathogenesis and treatment of nonalcoholic fatty liver disease. Med Rev. 2020; 26 (16): 3146- 3150 (in Chinese).

[35] Xu CF , Mu XL , Hu ZB , et al. Research progress on the pathogenesis of nonalcoholic fatty liver in Chinese and Western medicine. Hunan J Tradit Chin Med. 2018; 34 (6): 177- 179 (in Chinese).

[36] Zhao P , Jin H , Zhu JX . The role of interleukin-1β, interleukin-6 and tumor necrosis factor-α in the development of nonalcoholic fatty liver disease. Hainan Med. 2022; 33 (1): 96- 99 (in Chinese).

[37] Mota M , Banini BA , Cazanave SC , Sanyal AJ . Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease. Metabolism. 2016; 65 (8): 1049- 1061.

[38] Arroyave-Ospina JC , Wu Z , Geng Y , Moshage H . Role of oxidative stress in the pathogenesis of non-alcoholic fatty liver disease: implications for prevention and therapy. Antioxidants (Basel). 2021; 10 (2): 174.

[39] Miura K , Kodama Y , Inokuchi S , et al. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology. 2010; 139 (1): 323- 334.e7.

[40] Xu J , Shen J , Yuan R , Jia B , Zhang Y , Wang S . Mitochondrial targeting therapeutics: promising role of natural products in non-alcoholic fatty liver disease. Front Pharmacol. 2021; 12: 796207.

[41] Yang LY , Zhang H , Liu QQ . Research progress of MicroRNA in nonalcoholic fatty liver disease. Chin J Gerontol. 2021; 41 (23): 5444- 5447 (in Chinese).

[42] Chen L , Li YC , Sottas C , et al. Loss of mitochondrial ATPase ATAD3A contributes to nonalcoholic fatty liver disease through accumulation of lipids and damaged mitochondria. J Biol Chem. 2022; 298 (6): 102008.

[43] Lin ZY , Yang GW , Bai J , Huang J . Effects of ATAD3 gene cluster deletion on cerebellar dysfunction in mice by regulating mitochondrial DNA and cholesterol metabolism. J Guangxi Med Univ. 2021; 46 (6): 666- 672 (in Chinese).

[44] Horn CL , Morales AL , Savard C , Farrell GC , Ioannou GN . Role of cholesterol-associated steatohepatitis in the development of NASH. Hepatol Commun. 2022; 6 (1): 12- 35.

[45] Peralta S , Goffart S , Williams SL , Hetz C , Chevet E , Bailly-Maitre B . ATAD3 controls mitochondrial cristae structure in mouse muscle, influencing mtDNA replication and cholesterol levels. J Cell Sci. 2018; 131 (13): jcs217075.

[46] Schmid AI , Szendroedi J , Chmelik M , Krssak M , Moser E , Roden M . Liver ATP synthesis is lower and relates to insulin sensitivity inpatients with type 2 diabetes. Diabetes Care. 2011; 34 (2): 448- 453.

[47] Lu M , Lawrence DA , Marsters D , et al. Opposing unfolded-protein-response signals converge on death receptor 5 to control apoptosis. Science. 2014; 345 (6192): 98- 101.

[48] Lebeaupin C , Vallée D , Hazari Y , Hetz C , Chevet E , Bailly-Maitre B . Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease. J Hepatol. 2018; 69 (4): 927- 947.

[49] Arruda AP , Hotamisligil GS . Calcium homeostasis and organelle function in the pathogenesis of obesity and diabetes. Cell Metab. 2015; 22 (3): 381- 397.

[50] Yu Z . MiR-27a Induces Hepatic Steatosis through Down-Regulation NFE2L2. Jilin University; 2021: 1- 2 (in Chinese).

[51] Guo Y . miR-379/miR-544 Cluster Mediates High-Fat Diet-Induced Hepatic Steatosis and Its Role in Non-Alcoholic Fatty Liver Disease. Hubei University of Medicine; 2021: 36- 39 (in Chinese).

[52] Jobbins AM , Haberman N , Artigas N , et al. Dysregulated RNA polyadenylation contributes to metabolic impairment in non-alcoholic fatty liver disease. Nucleic Acids Res. 2022; 50 (6): 3379- 3393.

[53] Long JK , Dai W , Zheng YW , Zhao SP . miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease. Mol Med. 2019; 25 (1): 26.

[54] Lin Y , Ding D , Huang Q , et al. Downregulation of miR-192 causes hepatic steatosis and lipid accumulation by inducing SREBF1: novel mechanism for bisphenol A-triggered non-alcoholic fatty liver disease. Biochim Biophys Acta Mol Cell Biol Lipids. 2017; 1862 (9): 869- 882.

[55] Qin W , Wang JB , Wang LY , Zhuo Q , Yang Z . Mechanism of microRNA-29a regulating hepatocyte steatosis by silencing information regulator 2-related enzyme class 1 gene. J Hyg Res. 2021; 50 (2): 284- 288 (in Chinese).

[56] Ni YQ . Protective Effect of TRIM59 on High-Fat Diet-Induced Nonalcoholic Fatty Liver in Mice and Its Molecular Mechanism. Nanchang University; 2021 (in Chinese).

[57] Svegliati-Baroni G , Pierantonelli I , Torquato P , et al. Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease. Free Radic Biol Med. 2019; 144: 293- 309.

[58] Zhang YP , Tang KR , Deng YJ , et al. Effects of shenling baizhu powder herbal formula on intestinal microbiota in high-fat diet-induced NAFLD rats. Biomed Pharmacother. 2018; 102: 1025- 1036.

[59] Hao MJ , Dang YX , Zhou XX , et al. Effect of Huangqi San on AMPK/ACC/CPT1 pathway in hyperlipidemic rats. China J Chin Mater Med. 2018; 43 (12): 2586- 2590 (in Chinese).

[60] Lai SL . The Mechanism Study of Zhiganheji on Non-Alcoholic Fatty Liver Disease with Fatty Acid Metabolic Dysfunction. Guangzhou University of TCM; 2020 (in Chinese).

[61] Liu H , Peng H , Xiang H , et al. TWEAK/Fn14 promotes oxidative stress through AMPK/PGC1α/Mn SOD signaling path-way in endothelial cells. Mol Med Rep. 2018; 17 (1): 1998- 2004.

[62] Chen SZ , Liu XX , Peng C , et al. The phytochemical hyperforin triggers thermogenesis in adipose tissue via a Dlat-AMPK signaling axis to curb obesity. Cell Metab. 2021; 33 (3): 565. e7- 580.e7.

[63] Zhu XP , Bian H , Wang L , et al. Berberine attenuates non-alcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway. Free Radic Biol Med. 2019; 141: 192- 204.

[64] Zhuang ST , Zhang JL , Zou YQ , et al. Effect of Shihu mixture on autophagy protein of AMPK/TFEB signaling pathway in rats with T2DM-NAFLD. Chin J Exp Tradit Med Formulae. 2020; 26 (24): 53 (in Chinese).

[65] Li TT , Tan TB , Hou HQ , Zhao XY . Changes in peroxisome proliferator-activated receptor alpha target gene expression in peripheral blood mononuclear cells associated with non-alcoholic fatty liver disease. Lipids Health Dis. 2018; 17 (1): 256- 263.

[66] Francque S , Verrijken A , Caron S , et al. PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis. J Hepatol. 2015; 63 (1): 164- 173.

[67] Chi P . Progress in pathogenesis and drug development of nonalcoholic fatty liver disease. China Pharmacist. 2021; 24 (7): 338- 343 (in Chinese).

[68] Bi P , Kuang S . Notch signaling as a novel regulator of metabolism. Trends Endocrinol Metabol. 2015; 26 (5): 248- 255.

[69] Lu AM , Yu TG . Role of Hedgehog pathway in the development and progression of metabolic-dysfunction associated fatty liver disease. Chem Life. 2021; 41 (5): 983- 988 (in Chinese).

[70] Chen ZY , Pu R , Deng S , Liu M . N6-methyladenosine methylation and its regulation in metabolic diseases. Chin J Tissue Eng Res. 2022; 26 (20): 3250- 3255 (in Chinese).

[71] Liu J , Luo G , Sun J , et al. METTL14 is essential for β-cell survival and insulin secretion. Biochim Biophys Acta Mol Basis Dis. 2019; 1865 (9): 2138- 2148.

[72] Dou X , Xia Y , Chen J , et al. Rectification of impaired adipose tissue methylation status and lipolytic response contributes to hepatoprotective effect of betaine in a mouse model of alcoholic liver disease. Br J Pharmacol. 2014; 171 (17): 4073- 4086.

[73] Seimon TA , Nadolski MJ , Liao X , et al. Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab. 2010; 12 (5): 467- 482.

[74] Xiong J , Gu L , Wang Q , et al. Effect of TLR4/NF-κB signaling pathway on nonalcoholic fatty liver disease in CBS+/-mice. Chin J Pathophysiol. 2021; 37 (7): 1227- 1232 (in Chinese).

[75] Méndez-Sánchez N , Valencia-Rodríguez A , Coronel-Castillo C , et al. The cellular pathways of liver fibrosis in non-alcoholic steatohepatitis. Ann Transl Med. 2020; 8 (6): 400.

[76] Qian L , Ji J , Jiang Y , et al. Serpina3c deficiency induced necroptosis promotes non-alcoholic fatty liver disease through β-catenin/Foxo1/TLR4 signaling. FASEB J. 2022; 36 (5): e22316.

[77] Kozlitina J , Smagris E , Stender S , et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2014; 46 (4): 352- 356.

[78] Mahdessian H , Taxiarchis A , Popov S , et al. TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content. Proc Natl Acad Sci USA. 2014; 111 (24): 8913- 8918.

[79] Li ZZ , Zhang WT , Li R , et al. The role of autophagy in the pathogenesis and treatment of nonalcoholic fatty liver. Zhejiang J Integrated Tradit West Med. 2021; 31 (9): 883- 886 (in Chinese).

[80] Zang L , Liao Y , Xia Q , Zhou S , Li X . Ferroptosis regulatory signaling pathway and its research progress in related diseases. Chin J Clin Pharmacol Therapeut. 2022; 27 (2): 227- 234 (in Chinese).

[81] Tsurusaki S , Tsuchiya Y , Koumura T , et al. Hepatic ferroptosis plays an important role as the trigger for initiating inflammation in nonalcoholic steatohepatitis. Cell Death Dis. 2019; 10 (6): 449.

[82] Yu Y , Jiang L , Wang H , et al. Hepatic transferrin plays a role in systemic iron homeostasis and liver ferroptosis. Blood. 2020; 136 (6): 726- 739.

[83] Lei L , Peng Z . Mitochondrial dysfunction in nonalcoholic fatty liver disease and its therapeutic strategies. Chin J New Drugs. 2021; 30 (24): 2268- 2275 (in Chinese).

[84] Chipuk JE , Moldoveanu T , Llambi F , Parsons MJ , Green DR . The BCL-2 family reunion. Mol Cell. 2010; 37 (3): 299- 310.

[85] Liu W , Wu JP , Yuan PC , Shao T , Liu C , Wang G . Progress of research on the ameliorative effect and mechanism of Chinese herbal polysaccharides on nonalcoholic fatty liver disease. Chinese Herb Med. 2022; 53 (23): 7566- 7574 (in Chinese).

[86] Lin WY , Tian LM , Di BS , et al. Effects of p-ERK down-regulating sortilin expression on liver injury in non-alcoholic fatty liver rats. Chin J Pathophysiol. 2021; 37 (4): 680- 687 (in Chinese).

RIGHTS & PERMISSIONS

2024 2024 The Authors. Advanced Chinese Medicine published by John Wiley & Sons Australia, Ltd on behalf of Higher Education Press.